p53 stabilization and accumulation induced by human vaccinia-related kinase 1

Molecular and Cellular Biology

Volumn 24, Issue 23, 2004, Pages 10366-10380

  Vega, Francisco M ^a   Sevilla, Ana ^a   Lazo, Pedro A ^a,b  

^a Salamanca Spain   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN MDM2; PROTEIN P300; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VACCINIA RELATED KINASE 1;

ACETYLATION; ARTICLE; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; UBIQUITINATION; VACCINIA;

BLOTTING, WESTERN; CATALYSIS; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLOHEXIMIDE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; PHOSPHORYLATION; PLASMIDS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN SYNTHESIS INHIBITORS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; THREONINE; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

VACCINIA;

EID: 8644244682     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.23.10366-10380.2004     Document Type: Article

References (54)

1. Ahn, J., M. Urist, and C. Prives. 2003. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J. Biol. Chem. 278:20480-20489.
2. Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:3224-3233.
3. Ashcroft, M., and K. H. Vousden. 1999. Regulation of p53 stability. Oncogene 18:7637-7643.
4. Banham, A. H., and G. L. Smith. 1992. Vaccinia virus B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology 191:803-812.
5. Barcia, R., S. Lopez-Borges, F. M. Vega, and P. A. Lazo. 2002. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. Arch. Biochem. Biophys. 399:1-5.
6. Bargonetti, J., and J. J. Manfredi. 2002. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14:86-91.
7. 2 arrest after DNA damage. Science 282:1497-1501.
8. Craig, A., M. Scott, L. Burch, G. Smith, K. Ball, and T. Hupp. 2003. Allosteric effects mediate CHK2 phosphorylation of the p53 transactivation domain. EMBO Rep. 4:787-792.
9. Craig, A. L., L. Burch, B. Vojtesek, J. Mikutowska, A. Thompson, and T. R. Hupp. 1999. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342:133-141.
10. Dhillon, N., and M. F. Hoekstra. 1994. Characterization of two protein kinases from Schizosaccharomyces pombe involved in the regulation of DNA repair. EMBO J. 13:2777-2788.
11. Dornan, D., and T. R. Hupp. 2001. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2:139-144.
12. Dornan, D., H. Shimizu, L. Burch, A. J. Smith, and T. R. Hupp. 2003. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23:8846-8861.
13. Dornan, D., H. Shimizu, N. D. Perkins, and T. R. Hupp. 2003. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278:13431-13441.
14. Dornan, D., I. Wertz, H. Shimizu, D. Arnott, G. D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V. M. Dixit. 2004. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429:86-92.
15. Dumaz, N., and D. W. Meek. 1999. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18:7002-7010.
16. Dumaz, N., D. M: Milne, and D. W. Meek. 1999. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEES Lett. 463:312-316.
17. Garcia-Cao, I., M. Garcia-Cao, J. Martin-Caballero, L. M. Criado, P. Klatt, J. M. Flores, J. C. Weill, M. A. Blasco, and M. Serrano. 2002. Super p53′ mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:6225-6235.
18. Gatei, M., K. Sloper, C. Sorensen, R. Syljuasen, J. Falck, K. Hobson, K. Savage, J. Lukas, B. B. Zhou, J. Bartek, and K. K. Khanna. 2003. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J. Biol. Chem. 278:14806-14811.
19. Hemann, M. T., J. S. Fridman, J. T. Zilfou, E. Hernando, P. J. Paddison, C. Cordon-Cardo, G. J. Hannon, and S. W. Lowe. 2003. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33:396-400.
20. Jabbur, J. R., A. D. Tabor, X. Cheng, H. Wang, M. Uesugi, G. Lozano, and W. Zhang. 2002. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene 21:7100-7113.
21. Jabbur, J. R., and W. Zhang. 2002. p53 Antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20. Cancer Biol. Ther. 1:277-283.
22. 21a. Jackson, M. W., M. K. Agarwal, M. L. Agarwal, A. Agarwal, P. Stanhope-Baker, B. R. Williams, and G. R. Stark. 2004. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23:4477-4487.
23. Kamath, R. S., A. G. Fraser, Y. Dong, G. Poulin, R. Durbin, M. Gotta, A. Kanapin, N. Le Bot, S. Moreno, M. Sohrmann, D. P. Welchman, P. Zipperlen, and J. Ahringer. 2003. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421:231-237.
24. Kussie, P. H., S. Gorina, V. Marechal, B. Elenbass, J. Moreau, A. J. Levine, and N. P. Pavletich. 1996. Structure of the mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
25. Leng, R. P., Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J. M. Parant, G. Lozano, R. Hakem, and S. Benchimol. 2003. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112:779-791.
26. Li, M., C. L. Brooks, N. Kon, and W. Gu. 2004. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13:879-886.
27. Lin, S., W. Chen, and S. S. Broyles. 1992. The vaccinia virus B1R gene product is a serine/threonine protein kinase. J. Virol. 66:2717-2723.
28. Lopez-Borges, S., and P. A. Lazo. 2000. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene 19:3656-3664.
29. Lukas, C., J. Falck, J. Bartkova, J. Bartek, and J. Lukas. 2003. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol. 5:255-260.
30. Mancini, F., F. Gentiletti, M. D'Angelo, S. Giglio, S. Nanni, C. D'Angelo, A. Farsetti, G. Citro, A. Sacchi, A. Pontecorvi, and F. Moretti. 2004. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J. Biol. Chem. 279:8169-8180.
31. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
32. Meek, D. W. 1998. Multisite phosphorylation and the integration of stress signals at p53. Cell Signal. 10:159-166.
33. Milne, D. M., D. G. Campbell, F. B. Caudwell, and D. W. Meek. 1994. Phosphorylation of tumor suppressor protein p53 by mitogen-activated protein kinase. J. Biol. Chem. 269:9253-9260.
34. Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
35. Nezu, J., A. Oku, M. H. Jones, and M. Shimane. 1997. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45:327-331.
36. Pospisilova, S., V. Brazda, K. Kucharikova, M. G. Luciani, T. R. Hupp, P. Skladal, E. Palecek, and B. Vojtesek. 2004. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochem. J. 378:939-947.
37. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126.
38. Ryan, K. M., A. C. Phillips, and K. H. Vousden. 2001. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13:332-337.
39. Saito, S., H. Yamaguchi, Y. Higashimoto, C. Chao, Y. Xu, A. J. Fornace, Jr., E. Appella, and C. W. Anderson. 2003. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278:37536-37544.
40. Sakaguchi, K., S. Saito, Y. Higashimoto, S. Roy, C. W. Anderson, and E. Appella. 2000. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on mdm2 binding. J. Biol. Chem. 275:9278-9283.
41. Sakaguchi, K., H. Sakamoto, M. S. Lewis, C. W. Anderson, J. W. Erickson, E. Appella, and D. Xie. 1997. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36:10117-10124.
42. Sakaguchi, K., H. Sakamoto, D. Xie, J. W. Erickson, M. S. Lewis, C. W. Anderson, and E. Appella. 1997. Effect of phosphorylation on tetramerization of the tumor suppressor protein p53. J. Protein Chem. 16:553-556.
43. Sarkaria, J. N., E. C. Busby, R. S. Tibbetts, P. Roos, Y. Taya, L. M. Karnitz, and R. T. Abraham. 1999. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59:4375-4382.
44. Schon, O., A. Friedler, M. Bycroft, S. Freund, and A. Fersht. 2002. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323:491-501.
45. Sevilla, A., C. R. Santos, R. Barcia, F. M. Vega, and P. A. Lazo. c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene, in press.
46. Sevilla, A., C. R. Santos, F. M. Vega, and P. A. Lazo. 2004. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. J. Biol. Chem. 279:27458-27465.
47. Sherr, C., and F. McCormick. 2002. The RB and p53 pathways in cancer. Cancer Cell 2:103-112.
48. Stad, R., N. A. Little, D. P. Xirodimas, R. Frenk, A. J. van der Eb, D. P. Lane, M. K. Seville, and A. G. Jochemsen. 2001. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2:1029-1034.
49. 2/M transition by p53. Oncogene 20:1803-1815.
50. Vega, F. M., P. Gonzalo, M. L. Gaspar, and P. A. Lazo. 2003. Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. FEBS Lett. 544:176-180.
51. Vousden, K. H., and X. Lu. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604.
52. Wu, Z., J. Earle, S. Saito, C. W. Anderson, E. Appella, and Y. Xu. 2002. Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell. Biol. 22:2441-2449.
53. Xu, X., L. M. Tsvetkov, and D. F. Stern. 2002. Chk2 activation and phosphorylation-dependent oligomerization. Mol. Cell. Biol. 22:4419-4432.
54. Yuan, Z. M., Y. Huang, T. Ishiko, S. Nakada, T. Utsugisawa, H. Shioya, Y. Utsugisawa, K. Yokoyama, R. Weichselbaum, Y. Shi, and D. Kufe. 1999. Role for p300 in stabilization of p53 in the response to DNA damage. J. Biol. Chem. 274:1883-1886.